Fig. 6: MK-8776/olaparib combination reduces tumor growth in LAN-5 subcutaneous xenograft model.
From: A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
A WB analysis of tumor lysates explanted from LAN-5 xenografts treated for 30 h (n = 3/group). Blots were probed with the indicated antibodies and β-actin was used as loading control. The asterisk indicates the 89 kDa PARP1 cleaved fragment. B Bar plot representing the ratio between cleaved versus full length PARP1 expression assessed by densitometry (means ± SD) of the WB in (6A). C–D Evaluation of tumor growth and weight in LAN-5 xenografts after 2 weeks of treatment; data were expressed as mean volume + SEM and mean weight ± SEM (n = 10/group, CTR and MK + Ola n = 9). E Representative images of tumors explanted after 2 weeks of treatment.
